Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Announces Partnership with Versant Ventures and Inception Sciences

Published: Tuesday, February 05, 2013
Last Updated: Tuesday, February 05, 2013
Bookmark and Share
Roche to create Inception 3 for the treatment of sensorineural hearing loss.

Roche has announced that it has entered into an exclusive partnership with Versant Ventures and Inception Sciences to create a drug discovery incubator, Inception 3, for the treatment of sensorineural hearing loss.

Hearing impairment is a major global health issue with profound societal and economic impact affecting over 275 million people world-wide.

Sensorineural hearing loss is the most common type of permanent hearing loss and occurs when specialized sensory cells that detect sound (called hair cells) are injured, do not work correctly or have died.

The collaboration will focus on creating novel drug therapies that target inner ear hair cell protection and regeneration in the cochlea.

Under the terms of the agreement, Inception 3 will incorporate an innovative technology platform from Stanford University coupled with excellence in drug discovery from the ex-Amira Pharmaceuticals team at Inception Sciences, under the leadership of Peppi Prasit.

Versant will provide equity financing to the company and Roche will fund the research based on a series of milestones.

Roche retains an exclusive option to acquire Inception 3 upon a first lead compound reaching the filing stage of an investigational new drug (IND) application.

The occurrence of sensorineural hearing loss is rapidly rising, due to increasing noise exposure and aging populations. With no approved pharmaceutical therapies, the unmet medical need is very high.

“Our strategy at Roche Neuroscience is to focus on areas of unmet medical need where we understand the biological mechanism of disease” comments Luca Santarelli, Global Head of Roche Neuroscience.

Santarelli continued, “Due to significant advances in unraveling the biological basis of sensorineural hearing loss, we decided to build a significant external R&D effort in this area in partnership with world-class scientists, entrepreneurs and investors”.

“This deal structure is unique in that it enables us to pursue exciting, emerging science and develop it in partnership with venture capital and pioneers in this field” indicated Shafique Virani, Global Head of Neuroscience Partnering at Roche.

Virani continued, “The collaboration construct further gives us the flexibility in externalizing our R&D fixed cost base into an operationally nimble new company to achieve this.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche's Investigational Immunotherapy Shrank Bladder Cancer Tumors in Pivotal Study
The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.
Tuesday, July 14, 2015
Roche and InterMune Reach Definitive Merger Agreement
Roche to acquire InterMune for US$ 74.00 per share.
Thursday, August 28, 2014
FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Santaris Pharma
Acquisition to expand Roche's discovery and development of RNA-targeting medicines.
Tuesday, August 05, 2014
Roche Reports Promising Phase II Results with new Targeted Approach in Advanced Melanoma
BRAF inhibitor RG7204 shrank tumors in more than half of people with previously treated BRAF V600E mutation-positive metastatic melanoma.
Monday, November 15, 2010
Roche Buys Full Rights to Danoprevir from InterMune
Agreement reinforces Roche’s leadership in the fight against hepatitis C.
Wednesday, October 13, 2010
454 Sequencing Identifies Early Stage HIV Drug Resistance
Retrospective research study shows that even the lowest levels of resistance mutations could lead to early treatment failure.
Wednesday, February 18, 2009
Halozyme Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Halozyme grants exclusive, global rights to Roche for use of Enhanze™ Technology with biologics directed against fourth target.
Tuesday, December 09, 2008
Studies to Assess Risk of Exposure to Elevated Levels of EMS Confirm Clear Toxicity Threshold for DNA Damage
Studies emphasize lack of cancer risk for patients exposed to this impurity in Viracept.
Tuesday, August 05, 2008
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!